AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical UpdateNEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (
NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient mental health treatments, today announced fourth quarter and full year 2025 financial results and provided key regulatory, clinical and business updates.
